Valion Bio (VBIO) Consolidated Net Income (2021 - 2026)
Valion Bio (VBIO) posted quarterly Consolidated Net Income of $73000.0 for Q4 2025, up 104.83% year-over-year from $35638.5 in Q4 2024, and up 102.94% quarter-over-quarter from -$2.5 million in Q3 2025.
Valion Bio (VBIO) Consolidated Net Income (2021 - 2026) Analysis & Trends
Valion Bio's Consolidated Net Income history runs 5 years deep, the most recent figure standing at $73000.0 for Q4 2025.
- In Q4 2025, Consolidated Net Income rose 104.83% year-over-year to $73000.0; the TTM figure through Dec 2025 stood at -$5.8 million (down 0.81% YoY), while the FY2025 annual figure was -$885000.0, up 25.32% from the prior year.
- Consolidated Net Income for Q4 2025 stood at $73000.0, up from -$2.5 million in the prior quarter.
- The five-year high for Consolidated Net Income was $73000.0 in Q4 2025, with the low at -$3.1 million in Q2 2022.
- The 5-year median for Consolidated Net Income is -$1.9 million (2023), against an average of -$1.8 million.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income sank 140.06% in 2022, then surged 104.83% in 2025.
- Valion Bio's Consolidated Net Income stood at -$2.3 million in 2021, then declined by 0.65% to -$2.3 million in 2022, then grew by 0.48% to -$2.3 million in 2023, then surged by 34.23% to -$1.5 million in 2024, then jumped by 104.83% to $73000.0 in 2025.
- Business Quant data shows VBIO's Consolidated Net Income at $73000.0 in Q4 2025, -$2.5 million in Q3 2025, and -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.62 Mn |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | -2.48 Mn |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Dec 31, 2024 | -1.51 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.53 Mn |
| Dec 31, 2023 | -2.30 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.17 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -2.63 Mn |
| Jun 30, 2022 | -3.07 Mn |
| Mar 31, 2022 | -2.56 Mn |
| Dec 31, 2021 | -2.29 Mn |
| Sep 30, 2021 | -1.23 Mn |
| Jun 30, 2021 | -1.28 Mn |